Clinical Trials Logo

Non-Metastatic Prostate Cancer clinical trials

View clinical trials related to Non-Metastatic Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05617885 Active, not recruiting - Prostate Cancer Clinical Trials

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Start date: August 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a recommended dose for the second phase. The names of the study drugs and interventions involved in this study are: - Darolutamide - Abemaciclib - Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists It is expected that about 93 people will take part in the research study. Treatment is expected to last 6 months with a follow up period of up to 4.5 years.